Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis
The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
1. An isolated population of E4ORF1-expressing endothelial cells, wherein the isolated endothelial cells do not contain or express nucleic acid sequences that comprise the entire adenovirus E4 region.
2. A composition comprising an isolated population of endothelial cells according to claim 1 , further comprising a carrier solution.
3. The composition of claim 2 , wherein the carrier solution is a physiological saline solution.
4. A therapeutic composition comprising an isolated population of endothelial cells according to claim 1 and a carrier solution suitable for administration to a subject, wherein the endothelial cells are human umbilical vein endothelial cells.
5. The therapeutic composition of claim 4 , wherein the carrier solution is a physiological saline solution.
6. A cell composition comprising the E4ORF1-expressing endothelial cells according to claim 1 and a population of cancer cells, stem cells or progenitor cells.
7. A method of culturing cancer cells, stem cells or progenitor cells, the method comprising:
culturing the E4ORF1-expressing endothelial cells according to claim 1 in the same culture vessel with cancer cells, stem cells or progenitor cells.
8. The method of claim 7 , wherein the E4ORF1-expressing endothelial cells form a feeder cell layer in a culture vessel, and wherein the cancer cells, stem cells or progenitor cells are placed on the feeder cell layer.
9. The method of claim 7 , wherein the endothelial cells are primary endothelial cells.
10. The method of claim 7 , wherein the endothelial cells are human umbilical vein endothelial cells (HUVECs).
11. The method of claim 7 , wherein the stem cells are hematopoietic stem cells or embryonic stem cells.
12. The method of claim 7 , wherein the stem cells are hematopoietic stem cells and wherein the endothelial cells and the hematopoietic stem cells are grown in the absence of serum.
13. The method of claim 7 , wherein the stem cells are embryonic stem cells and wherein the endothelial cells and the embryonic stem cells are grown in the absence of serum.
14. A method of culturing cancer cells, stem cells or progenitor cells, the method comprising:
(a) culturing the E4ORF 1-expressing endothelial cells according to claim 1 in a culture vessel;
(b) collecting conditioned medium from the culture vessel; and
(c) adding the conditioned medium to a culture of cancer cells, stem cells or progenitor cells.
15. A method for maintaining or expanding endothelial cells in culture, comprising:
(a) introducing a nucleic acid sequence encoding adenovirus E4ORF1 under the control of a promoter into isolated endothelial cells such that the endothelial cells express E4ORF1 to a level sufficient to maintain or expand the isolated endothelial cells in culture, wherein the endothelial cells do not contain or express nucleic acid sequences that comprise the entire adenovirus E4 region; and
(b) culturing the isolated endothelial cells expressing E4ORF1.
16. The method of claim 15 , wherein the step of introducing is performed by transfection.
17. The method of claim 16 , wherein the transfection is performed using a method selected from the group consisting of liposome-mediated transfection, polybrene-mediated transfection, DEAE dextran-mediated transfection, electroporation, calcium phosphate precipitation, microinjection, or micro-particle bombardment.
18. The method of claim 15 , wherein the step of introducing is performed by viral-mediated transduction.
19. The method of claim 18 , wherein the viral-mediated transduction is selected from the group consisting of lentivirus-mediated transduction, adenovirus-mediated transduction, retrovirus-mediated transduction, adeno-associated virus-mediated transduction and herpesvirus-mediated transduction.
20. The method of claim 15 , wherein the step of culturing is performed in the absence of serum.
21. The method of claim 15 , wherein the step of culturing is performed in the absence of exogenous growth factors.
22. The method of claim 15 , wherein the endothelial cells are primary endothelial cells.